| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 8.105 | 24.657 | 26.686 | 18.112 | 3.997 | 6.313 | 18.369 |
| Total Income - EUR | - | - | - | 8.105 | 24.657 | 26.686 | 18.126 | 3.997 | 6.313 | 18.371 |
| Total Expenses - EUR | - | - | - | 3 | 34 | 72 | 59 | 66 | 140 | 75 |
| Gross Profit/Loss - EUR | - | - | - | 8.101 | 24.623 | 26.614 | 18.068 | 3.931 | 6.173 | 18.295 |
| Net Profit/Loss - EUR | - | - | - | 7.858 | 23.884 | 25.814 | 17.524 | 3.811 | 5.185 | 15.368 |
| Employees | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Oncology Performance S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | 8.144 | 24.933 | 27.048 | 18.152 | 4.525 | 5.769 | 16.917 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 0 | 0 | 706 | 374 | 0 | 710 | 893 |
| Cash | - | - | - | 8.144 | 24.933 | 26.341 | 17.778 | 4.525 | 5.059 | 16.024 |
| Shareholders Funds | - | - | - | 7.901 | 23.936 | 25.907 | 17.615 | 3.903 | 5.276 | 15.458 |
| Social Capital | - | - | - | 43 | 42 | 83 | 81 | 81 | 81 | 80 |
| Debts | - | - | - | 243 | 997 | 1.141 | 536 | 622 | 493 | 1.458 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Oncology Performance S.r.l.